Biotechnology Company Announces Partnership With Healthcare Giant Johnson & Johnson

In a significant move towards advancing healthcare for the most vulnerable, Rallybio Corporation has announced a groundbreaking collaboration with healthcare giant Johnson & Johnson. This partnership is poised to usher in a new era of therapeutic approaches aimed at mitigating the risks associated with fetal and neonatal alloimmune thrombocytopenia (FNAIT), a rare but potentially life-threatening condition that affects fetuses and newborns. $Rallybio(RLYB.US)$